Published: 2021-04-21 11:41
Last Updated: 2021-05-06 09:31
Wednesday, the General Director of the Jordan Food and Drug Administration (JFDA) Nizar Muhaidat said that there have not been any reports regarding blood clotting in recipients of the Oxford-AstraZeneca COVID-19 vaccine in Jordan.
Muhaidat told the Jordan News Agency (Petra) that all reports received by the JFDA from these recipients involved normal side effects and 'nothing unusual.'
"General side effects include fatigue, headache, muscle pain, joint pain, chills, fever, nausea and vomiting," he added.